Novo News: Boardroom Rift Expected to Refocus Drugmaker on U.S. Growth Strategy
We’ve reached a turning point at Novo. The Danish drugmaker known for its blockbuster weight-loss treatment has seen a boardroom shake-up: its chair and several independent directors are stepping down.
This is more than just a governance drama. It’s a signal of a strategic reset. Novo’s biggest shareholder has pushed for change and now wants the company to better capture the U.S. market. We’ll walk through what led to the shake-up, how the U.S. strategy is evolving, what risks lie ahead, and what to watch.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
